SEED AND ANGEL FINANCING FOR LIFE SCIENCE COMPANIES

When:
January 21, 2020 @ 6:00 pm – 9:00 pm America/New York Timezone
2020-01-21T18:00:00-05:00
2020-01-21T21:00:00-05:00
Where:
Draper Labs, Hill Building
One Hampshire Street
Cambridge
MA

Entrepreneur’s Network

Registration:

ENET Member – Free
Non-ENET Member – $10.00

Register at:

Life sciences entrepreneurs derive from a wide variety of geographic and educational backgrounds. Young or old(er), most share a strong passion for translating their ideas and data into commercial products and services to benefit human health. While the work is rewarding, it is a tremendously challenging endeavor, from building the team to meeting regulatory requirements. Often, the most daunting challenge is raising the financing needed to get started. The panelists for tonight’s ENET event have deep experience in launching life science startups, from the perspectives of founder and investor, and they are looking forward to sharing their insights with you. Please join us for an engaging discussion and stellar networking.

Agenda:

6:00-7:00 PM – Registration & networking
7:00-7:10 PM – ENET Chairperson’s announcements
7:10-7:25 PM – eMinute – Up to 3 Startup companies’ presentations
7:25-8:15 PM – Two expert speakers on the night’s topic
8:15- 8:30 PM – Audience / Speakers Q & A
8:30 – 9:00 PM – Final networking includes meeting presenting speakers

A question and answer session follow the presentation, and panelists will be available afterward for responses to individual questions. As with every ENET meeting, you will also get the chance to network with the panelists and other meeting attendees, both before the start of the meeting and afterward.

Panel:

Maria Berkman, MD, MBA, Director, Head of MedTech, Broadview Ventures, Inc.

Maria shares responsibility for all aspects of Broadview’s investment activity, from identification and screening of new opportunities, through due diligence, negotiation of deal structure, and portfolio company board involvement.

Prior to joining Broadview Ventures, Maria was a management consultant at Monitor Group, where she specialized in life sciences with a focus on corporate, franchise, and asset-level commercialization strategy and competitive strategic planning for both BioPharma and MedTech clients. Prior to joining Monitor Group, Maria trained within the Partners HealthCare System at Newton Wellesley Hospital in General Surgery. Maria earned an MD from the UCLA School of Medicine, graduating Alpha Omega Alpha with a research focus in cardiothoracic and trauma surgery, and earned an MBA from the Anderson School of Management at UCLA.

In addition to her role at Broadview Ventures, Maria contributes time as a SBIR/STTR grant reviewer for the National Science Foundation and is a Strategic Advisory Board Member for the RAD BioMed Accelerator in Tel Aviv, Israel.

Patrice M. Milos, Ph.D. Co-Founder/President and CEO, Medley Genomics Inc.

Dr. Milos co-founded Medley Genomics to deliver novel data analytics for understanding the heterogeneity of complex diseases with an initial focus in oncology. Immediately prior, Patrice was CEO of Claritas Genomics, a pediatric molecular diagnostic company spin-out from Boston Children’s Hospital. Dr. Milos was Boston Site Head for Pfizer’s Centers of Therapeutic Innovation, establishing academic-medical center partnerships to advance novel therapies to treat human disease. She was also SVP/CSO for Helicos BioSciences in Cambridge, MA, and Executive Director for Pfizer Inc, responsible for leading genomics supporting the Pfizer portfolio in precision medicine. Currently, Dr. Milos chairs the Board of Directors for RI Bio, is on the board of RI Venture Mentoring Services and recently served on the European Commission funded ULTRAPLACAD External Advisory Board. Patrice is also Senior Advisor to Binx Health and SeqLL. Patrice earned her MS/PhD at Rensselaer Polytechnic Institute with postdoctoral fellowships at Brown and Harvard.

Gitte Pedersen, CEO, Genomic Expression

Gitte Pedersen is a scientist/CEO with a mission to cure cancer. Gitte started Genomic Expression together with her brother, Morten Pedersen, after her parents were diagnosed with cancer understanding that if they did standard of care none of them would survive. Morten developed a way to sequence RNA in tumor tissue and connect alterations to already approved drugs and clinical studies while Gitte raised raised $8M, $6.5M in grants, to clinically validate their technology in 4 types of cancer. The OneRNA™ platform enables a paradigm shift from ONE disease, ONE marker, and ONE drug to ONE patient, MANY markers, and MULTIPLE treatment options that go beyond drugs.

Gitte got Genomic Expression into the top 10 of the XTC, presented for Richard Branson at Necker island, won the Lyfebulb and the EUTop50 award, and presented at the European Parliament. Prior to Genomic Expression, Gitte advised multiple small and medium sized biotech companies as well as the Danish Ministry of Foreign Affairs. Her deal resume is +$1B. She worked at Novo Nordisk in a number of management positions and brought multiple products to market worldwide. Gitte has a master in Chemical Engineering and a bachelor in International Trade. Gitte recently joined Pipeline Angels and made her first angel investment. She co-founded Female Equity (www.femaleequity.org) which is a network organization for female founders and investors having fun(d) paddle boarding.

Moderator/Organizer

Roger Frechette, Ph.D., Founder and Principal, NEPAssociates

My daily purpose is to exercise an innate drive to transform ideas and projects into life-changing commercial assets. In the life science business, this is the long game, requiring boundless energy and creativity, coupled with knowledge, experience, and patience.

In my consulting work, I leverage an extensive global network and insights derived from >20 years of experience in business development, calibrated with an extensive science background. My career has encompassed success as a business executive, project/alliance manager and entrepreneur, and also as a scientist, including leadership of discovery/preclinical development teams resulting in a new drug candidate – Paratek Pharmaceuticals NDA’s for NUZYRA and SEYSARA NDA’s were approved in 2018.

Reservations: Please register at:

This ENET meeting is free to ENET members and $10 for non-members. To expedite sign-in and order refreshments for the meeting, we ask that everyone — members as well as non-members — pre-register for the meeting online. If you cannot pre-register, you are welcome to register at the door.
REFRESHMENTS: Pizza, salad, and soft drinks will be served at this meeting.

LOCATION: Draper, Hill Building, One Hampshire St. Cambridge, MA 02139. The address is One Hampshire St, but the entrance is actually on Broadway. Attendees must arrive at Draper before 7 pm. Entrance is locked after 7 pm.

PUBLIC TRANSPORTATION: Kendall Square stop on the Red Line.